Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate the clinical effectiveness of MK0812 in the treatment of Arthritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Oxymetazoline

Criteria

Inclusion Criteria:

• Patient has had diagnosis of RA made at least 6 months prior to study start and was greater than 16 years of age when diagnosed

• Patient has active RA with a minimum level of disease activity including at least 10 swollen joints and 10 tender or painful joints

• Excepting rheumatoid arthritis, patient is judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests

Exclusion Criteria:

• Patient is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of psychosis

• Patient has a history of any clinically significant disease of the cardiovascular, hepatic, neurological, renal, genitourinary, or hematologic systems or uncontrolled blood pressure

• Female patient is pregnant or breast-feeding